Kohlberg Kravis Roberts

Ducommun Incorporated Announces the Appointment of Suman Mookerji to Senior Vice President, Chief Financial Officer, Controller and Treasurer

Retrieved on: 
Wednesday, May 3, 2023
Suman, University, Employment, Ernst & Young, Raytheon Technologies, Arthur Andersen, Babson College, MBA, KKR, Kohlberg Kravis Roberts, History, DCO, Acquisition, Capital Safety, United Technologies, NYSE, Management, Ducommun

Mr. Christopher D. Wampler, Ducommun’s former vice president, chief financial officer, controller & treasurer will continue his employment with the Company in a non-executive capacity to facilitate a smooth transition of responsibilities.

Key Points: 
  • Mr. Christopher D. Wampler, Ducommun’s former vice president, chief financial officer, controller & treasurer will continue his employment with the Company in a non-executive capacity to facilitate a smooth transition of responsibilities.
  • "I am pleased to announce the promotion of Suman to be the next chief financial officer, controller and treasurer of Ducommun, and want to express my gratitude to Chris for his hard work and dedication to the Company,” said Stephen G. Oswald, chairman, president, and chief executive officer of Ducommun Incorporated.
  • For the last year and a half, Mr. Mookerji served as vice president, corporate development & investor relations.
  • Mr. Mookerji holds an MBA from Babson College and a bachelor’s degree from the University of Mumbai.

ClinOne Closes Series A Funding Round to Scale its Site and Participant Engagement platform, Data Driven Insights and Interoperability

Retrieved on: 
Thursday, April 13, 2023
Kohlberg Kravis Roberts, Medicine, Partnership, Central Waqf Council, ARCA, ERT, Consent management, Health care, Clinical trial, Arbutus Biopharma, ICON, General partnership, Investment company, ICON PLC, Patient, Community, Genstar Capital, Growth, Health, Environment, Caregiver, Pharmaceutical industry

BOSTON and BOULDER, Colo., April 13, 2023 /PRNewswire-PRWeb/ -- ClinOne, the leading provider of Adaptive Experiences in clinical trials announced today it closed a $3 million Series A funding to accelerate the growth of its platform and broaden its reach to serve customers. This latest round, led by Boulder Ventures, with participation from existing investors CU Healthcare Innovation Fund and First Trust Capital Partners, will continue to advance ClinOne's mission to offer flexible engagement solutions for all participants to support their clinical trial journey.

Key Points: 
  • As part of this investment, Robert Conway will join the ClinOne Board as Executive Chair.
  • ClinOne sells an integrated platform that offers comprehensive support for sites, participants, and caregivers throughout the clinical trial journey.
  • ClinOne has built a platform which offers ease of use along with comprehensiveness and efficiency for all stakeholders to meet.
  • ClinOne makes their participation in clinical trials simple, reliable, and useful, and by offering flexibility, can reach a diverse group of participants.

Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

Retrieved on: 
Tuesday, March 21, 2023
Kohlberg Kravis Roberts, Trade, Strategic planning, National Association of Corporate Directors, Business, RBP, Marketing, Business administration, Marshall University, Corporation, National Association, FTSE, FDA, Management, Indivior

The Keswick Group is led by Tony Goodman, a current member of Adial’s board of directors.

Key Points: 
  • The Keswick Group is led by Tony Goodman, a current member of Adial’s board of directors.
  • Mr. Goodman’s career spans over 23 years in the pharmaceutical and biotech industries.
  • He is the founder and Managing Director of The Keswick Group, LLC.
  • Mr. Goodman has also served as the Director of Strategic Marketing and Business Development at PRA International.

Illumix Closes Series A Round Funding, Strengthening Its Position as a Leading Tech Company Bridging the Digital and Physical Worlds

Retrieved on: 
Monday, March 20, 2023
Metaverse, Speed of light, 3D, General partnership, Kohlberg Kravis Roberts, KKR, OV, Epyllion, Acquisition, SAN, Commerce, Maveron, AR, Video game, Online shopping

Also joining this round of funding are Mark Cuban of “Shark Tank,” Sony Innovation Fund, RW3 Ventures, OV, Visible Ventures and Xavier Niel.

Key Points: 
  • Also joining this round of funding are Mark Cuban of “Shark Tank,” Sony Innovation Fund, RW3 Ventures, OV, Visible Ventures and Xavier Niel.
  • Illumix has helped lead the global progression from passive 2D digital experiences to 3D immersive experiences through its seamless cross-platform infrastructure.
  • Illumix has already powered over 300 million digital-physical interactions across web and mobile in the past two years alone.
  • This round of funding will accelerate the company’s continued expansion to new categories, as the company propels the digital-physical evolution forward.

Raymond J. McGuire Joins Lazard as President

Retrieved on: 
Wednesday, March 8, 2023
Banking, Asset Management, Professional Services, Finance, Entomology, Whitney Museum, Citigroup, First Boston, Investment banking, KKR, NYSE, Regional Plan Association, Vornado Realty Trust, Whitney, Vice, National Jazz Museum in Harlem, Wasserstein Perella & Co., Judgement, LTD, Morgan Stanley, LAZ, American Museum, Corporation, Kohlberg Kravis Roberts, Mecum Dealmakers, Mergers and acquisitions, Wall Street, Hess Corporation, Multimedia, Merrill (company), Capital market, NewYork-Presbyterian Hospital, Studio Museum in Harlem, McGuire family, Hospital, Natural history, Management

Lazard Ltd (NYSE: LAZ) today announced that Raymond J. McGuire has joined the firm as President, effective April 3, 2023.

Key Points: 
  • Lazard Ltd (NYSE: LAZ) today announced that Raymond J. McGuire has joined the firm as President, effective April 3, 2023.
  • (Photo: Business Wire)
    “We are privileged to have Ray join us and serve in a senior leadership role.
  • He subsequently became one of the original members of Wasserstein Perella & Co., where he was named a Partner/Managing Director in 1991.
  • Mr. McGuire has an extensive record of service on both corporate and not-for-profit boards.

Business Council Elects Gail K. Boudreaux as Chair

Retrieved on: 
Wednesday, February 8, 2023
Professional Services, Public Policy, Government, Business, Other Professional Services, Thought Leadership, Insurance, Advocacy Group Opinion, Nike, Pharmacy, The Business Council, Cargill, Microsoft, Health, Executive Committee, Kohlberg Kravis Roberts, NIKE, TIAA, Elevance Health, Management

The Business Council today announced that Gail Boudreaux, president and CEO of Elevance Health, has been appointed to serve as chair of the Business Council.

Key Points: 
  • The Business Council today announced that Gail Boudreaux, president and CEO of Elevance Health, has been appointed to serve as chair of the Business Council.
  • Boudreaux will be the first woman to chair the Business Council in the group’s nearly 90-year history.
  • “I am incredibly honored to serve as the next chair of the Business Council at a pivotal time in our society,” said Gail K. Boudreaux, president and CEO, Elevance Health.
  • We are fortunate to have her leading the Business Council in the coming years.”
    “I can’t think of a better leader to serve as the next chair of The Business Council,” said Marlene M. Colucci, CEO of The Business Council.

KNBE Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of KnowBe4, Inc. to Vista Equity Partners

Retrieved on: 
Tuesday, December 20, 2022
Vista Equity Partners, KNBE, Committee, File, Wohl, Investment, Special, Kohlberg Kravis Roberts, Select or special committee (United States Congress), Sale, Security (finance)

MONSEY, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the members of the Special Committee of the Board of Directors of KnowBe4, Inc. (Nasdaq: KNBE) (“KNBE”) that recommended the sale of KNBE to Vista Equity Partners (“Vista”) for $24.90 per share in cash were truly independent and disinterested as claimed in a recent SEC filing.

Key Points: 
  • MONSEY, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the members of the Special Committee of the Board of Directors of KnowBe4, Inc. (Nasdaq: KNBE) (“KNBE”) that recommended the sale of KNBE to Vista Equity Partners (“Vista”) for $24.90 per share in cash were truly independent and disinterested as claimed in a recent SEC filing.
  • On October 12, 2022, KNBE announced that it had agreed to be acquired by Vista for $24.90 per share in cash.
  • The agreement was approved by the KNBE Board of Directors (“Board”) upon the recommendation of a Special Committee of the Board.
  • A recent SEC filing indicates that several of KNBE’s largest stockholders are “rolling over” a portion of their KNBE shares into ownership interests in the Vista affiliate that is acquiring KNBE.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares

Retrieved on: 
Sunday, November 27, 2022
Inflammation, Euroclear, Financial Services and Markets Act 2000, Therapy, European Economic Area, Protein, Drug development, Security (finance), Communication, AFRICA, Kohlberg Kravis Roberts, Qualifying investor alternative investment fund, Patient, Financial services, Prospectus, Risk, Fibrosis, Person, Relevance (Person of Interest), Issuer, KKR, European Union (Withdrawal) Act 2018, Disease, EUR, AMERICA, Urban economics, Council, Sale, Cancer, Article, European Parliament, Euronext Amsterdam, Investment, Pharmaceutical industry, EU

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.

Key Points: 
  • NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
  • Vivoryon is pioneering a unique therapeutic approach to overcoming the challenges in Alzheimers disease ("AD") drug development.
  • Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines.
  • Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

Retrieved on: 
Sunday, November 27, 2022
National Institute on Aging, Data collection, KKR, Acute kidney injury, Inflammation, MCI, PHASE 2, Kohlberg Kravis Roberts, Cancer, Partnership, Therapy, ADCS, AD, Patient, Exercise, Protein, Homeostasis, Research, Q&A, Nature Communications, Monash University, VIVA, EUR, CET, Risk, Immunity, NIA, Fibrosis, Euronext Amsterdam, Clinical trial, Safety, EU, Probability, Security (finance), Pharmaceutical industry, Medical imaging, Renewable energy, Broadcasting

In the third quarter of 2022, we were very pleased to have strengthened our financial position with a successful private placement of up to EUR 30 million.

Key Points: 
  • In the third quarter of 2022, we were very pleased to have strengthened our financial position with a successful private placement of up to EUR 30 million.
  • Vivoryon now expects to report full data, including additional follow-up data, in the first quarter of 2024.
  • A Q&A session will follow the presentation of the third quarter results and operational progress.
  • Certain risk factors that may affect the Companys future financial results are discussed in the published annual financial statements of the Company.

Laureate Education Announces the Pricing of an Underwritten Public Offering by Selling Stockholders

Retrieved on: 
Friday, November 18, 2022
Kohlberg Kravis Roberts, Hand, Attention, Telephone, Student, Education, Prospectus, Annual report, File, Laureate Education, Strategic Education, Inc., Laureate, University, Security (finance), Sale, Tiger, Form, Share repurchase, Borrowing center

MIAMI, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR) (the Company) today announced the pricing of the underwritten secondary offering by certain existing stockholders affiliated with Kohlberg Kravis Roberts & Co. L.P. (the Selling Stockholders) of 32,842,183 shares of the Companys common stock.

Key Points: 
  • MIAMI, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR) (the Company) today announced the pricing of the underwritten secondary offering by certain existing stockholders affiliated with Kohlberg Kravis Roberts & Co. L.P. (the Selling Stockholders) of 32,842,183 shares of the Companys common stock.
  • The Selling Stockholders have agreed to sell the shares of our common stock pursuant to this secondary offering at a public offering price of $9.75 per share.
  • The Company is not selling any shares and will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders.
  • The offering is expected to close on November 22, 2022 and is subject to customary closing conditions.